NLRP1 and neoplasm: Our finding of a positive regulation of NLRP1 expression by miR-34a raises the possibility that pharmacological treatment of cSCC patients with mimics of the miR might increase anti-tumor immunity and other tumor suppressive effects downstream of NLRP1 [21].